Abstract:Adenosine-to-inosine (A-to-I) RNA editing, catalyzed by the adenosine deaminase acting on the RNA (ADAR) family of enzymes of which there are three members (ADAR1, ADAR2, and ADAR3), is a major gene regulatory mechanism that diversifies the transcriptome. It is widespread in many metazoans, including humans. As inosine is interpreted by cellular machineries mainly as guanosine, A-to-I editing effectively gives A-to-G nucleotide changes. Depending on its location, an editing event can generate new protein isoforms or influence other RNA processing pathways. Researchers have found that ADAR-mediated editing performs diverse functions. For example, it enables living organisms such as cephalopods to adapt rapidly to fluctuating environmental conditions such as water temperature. In development, the loss of ADAR1 is embryonically lethal partly because endogenous double-stranded RNAs (dsRNAs) are no longer marked by inosines, which signal "self", and thus cause the melanoma differentiation-associated protein 5 (MDA5) sensor to trigger a deleterious interferon response. Hence, ADAR1 plays a key role in preventing aberrant activation of the innate immune system. Furthermore, ADAR enzymes have been implicated in myriad human diseases. Intriguingly, some cancer cells are known to exploit ADAR1 activity to dodge immune responses. However, the exact identities of immunogenic RNAs in different biological contexts have remained elusive. Consequently, there is tremendous interest in identifying inosine-containing RNAs in the cell.The identification of A-to-I RNA editing sites is dependent on the sequencing of nucleic acids. Technological and algorithmic advancements over the past decades have revolutionized the way editing events are detected. At the beginning, the discovery of editing sites relies on Sanger sequencing, a first-generation technology. Both RNA, which is reverse transcribed into complementary DNA (cDNA), and genomic DNA (gDNA) from the same source are analyzed. After sequence alignment, one would require an adenosine to be present in the genome but a guanosine to be detected in the RNA sample for a position to be declared as an editing site. However, an issue with Sanger sequencing is its low throughput. Subsequently, Illumina sequencing, a second-generation technology, was invented. By permitting the simultaneous interrogation of millions of molecules, it enables many editing sites to be identified rapidly. However, a key challenge is that the Illumina platform produces short sequencing reads that can be difficult to map accurately. To tackle the challenge, we and others developed computational workflows with a series of filters to discard sites that are likely to be false positives. When Illumina sequencing data sets are properly analyzed, A-to-G variants should emerge as the most dominant mismatch type. Moreover, the quantitative nature of the data allows us to build a comprehensive atlas of editing-level measurements across different biological contexts, providing deep insights into the spatiotemporal dynamics of RNA editing. However, difficulties remain in identifying true A-to-I editing sites in short protein-coding exons or in organisms and diseases where DNA mutations and genomic polymorphisms are prevalent and mostly unknown. Nanopore sequencing, a third-generation technology, promises to address the difficulties, as it allows native RNAs to be sequenced without conversion to cDNA, preserving base modifications that can be directly detected through machine learning. We recently demonstrated that nanopore sequencing could be used to identify A-to-I editing sites in native RNA directly. Although further work is needed to enhance the detection accuracy in single molecules from fewer cells, the nanopore technology holds the potential to revolutionize epitranscriptomic studies.

Identification of Diverse Adenosine-to-Inosine RNA Editing Subtypes in Colorectal Cancer

The expression of RNA editing enzymes in the tissue of colorectal carcinoma

Recent Advances in Adenosine-to-Inosine RNA Editing in Cancer

Identification of A-to-I RNA Editing Profiles and Their Clinical Relevance in Lung Adenocarcinoma

A-to-I Editing Is Subtype-Specific in Non-Hodgkin Lymphomas

A-to-I Editing Sites Are a Genomically Encoded G: Implications for the Evolutionary Significance and Identification of Novel Editing Sites

Global Analysis of A-to-I RNA Editing Reveals Association with Common Disease Variants

ADAR-mediated RNA Editing in Non-Coding RNA Sequences

ADAR1-Mediated RNA Editing and Its Role in Cancer

Abstract 6250: The RNA editing landscape of lung cancer in never smokers

The effects of RNA editing in cancer tissue at different stages in carcinogenesis

Abstract 4635: Inherited Variants Affecting RNA Editing May Contribute to Ovarian Cancer Susceptibility

Tissue and Exosomal Mirna Editing in Non-Small Cell Lung Cancer.

Identification of Bona Fide RNA Editing Sites: History, Challenges, and Opportunities

Non-Coding RNA Editing in Cancer Pathogenesis

A-to-I nonsynonymous RNA editing was significantly enriched in the ubiquitination site and correlated with clinical features and immune response

ADARs, RNA editing and more in hematological malignancies

Comprehensive Characterization of the RNA Editomes in Cancer Development and Progression.

A Disrupted RNA Editing Balance Mediated by ADARs (adenosine DeAminases That Act on RNA) in Human Hepatocellular Carcinoma

Adenosine-to-Inosine RNA Editing: A Key RNA Processing Step Rewriting Transcriptome in Normal Physiology and Diseases

ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer